Robert H Vonderheide

Title: The Innovative Contributions of Robert H. Vonderheide

Introduction

Robert H. Vonderheide is a prominent inventor based in Brookline, MA, known for his significant contributions to cancer immunotherapy. With a total of three patents to his name, Vonderheide has made strides in the field of cancer diagnosis and treatment, focusing on universal tumor-associated antigens.

Latest Patents

Vonderheide's latest patents include groundbreaking inventions in cancer immunotherapy. One of his notable patents is titled "Cancer immunotherapy and diagnosis using universal tumor associated antigens, including hTERT." This invention provides methods for conducting cancer immunotherapy and diagnosis using universal tumor-associated antigens, such as the telomerase catalytic subunit (hTERT). It also outlines methods for identifying and characterizing these universal tumor-associated antigens. Another significant patent is "Cancer immunotherapy and diagnosis using cytochrome P450 1B1." This invention offers methods for conducting cancer immunotherapy and diagnosis using cytochrome P450 1B1 and peptide fragments thereof.

Career Highlights

Throughout his career, Vonderheide has worked with esteemed organizations such as the Dana-Farber Cancer Institute Inc. and the Center for Blood Research, Inc. His work in these institutions has contributed to advancements in cancer research and treatment methodologies.

Collaborations

Vonderheide has collaborated with notable colleagues, including Joachim L. Schultze and Lee M. Nadler. These collaborations have further enhanced his research and innovation in the field of cancer immunotherapy.

Conclusion

Robert H. Vonderheide's innovative work in cancer immunotherapy and his contributions to the understanding of tumor-associated antigens have made a significant impact in the medical field. His patents reflect a commitment to advancing cancer treatment and improving patient outcomes.